Amgen stock gains as guidance and Repatha lift outlook

Published on 09/03/2026 at 09:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock trades near USD 439.51 as investors weigh a higher 2026 outlook, a 9.5 percent revenue increase in Q2 2026 and Repatha sales momentum.

Editorial-Aufnahme eines Nasdaq-Handelssaals mit großen Bildschirmen und steigenden Biotech-Sektor-Kurscharts — Amgen Inc. (ISIN US0311621009) thematisiert dieses Börsen-Editorial mit Nasdaq-Handelssaal und ansteigenden Biotech-Sektor-Kurscharts auf großen Bildschirmen, Illustration mit AI erstellt.

Amgen stock (US0311621009) traded at USD 439.51 on September 3, 2026, with a market capitalization of USD 239.41 billion, while the shares moved between USD 435.00 and USD 445.57 during the session. A Reuters-linked market note and a fresh conference announcement both keep the name in view as the company heads toward its next investor presentation.

Higher guidance still matters

According to MarketBeat, Amgen reported Q2 2026 earnings of USD 6.29 a share on revenue of USD 10.05 billion, compared with consensus for USD 5.62 and USD 9.43 billion. Revenue rose 9.5 percent year over year, and the company raised FY 2026 guidance to USD 22.30 to USD 23.50 in non-GAAP EPS.

The comparison is the key point for investors: the quarterly EPS beat was USD 0.67, and the revenue beat was USD 0.62 billion. MarketBeat also said the consensus analyst rating is Hold, with a price target of USD 380.43, below the current share price.

Repatha adds a second leg

Amgen's cardiovascular drug Repatha is the most concrete operating driver in the current news flow. MarketBeat cited company data showing that Repatha reduced the risk of death by 20 percent in more than 12,000 high-risk patients in the VESALIUS-CV study, and separate coverage put second-quarter 2026 Repatha sales at USD 953 million, up 37 percent year over year.

That mix helps explain why the stock can stay firm even with the UK suspension of Tavneos for new patients still in the background. For investors, the important question is whether Repatha can keep translating clinical data into sales growth through the second half of 2026.

Go deeper

Amgen, guidance and the next catalyst

Amgen is moving between higher 2026 guidance, Repatha growth and a market price that already sits above the latest consensus target.

Amgen coverage Investor Relations

Repatha is the product to watch

Repatha remains the best current example of how Amgen can turn clinical readouts into commercial scale. The product contributed USD 953 million in second-quarter 2026 sales, and the 37 percent increase gives the business a visible growth rate that is not tied only to pricing or buybacks.

Price stays elevated

Amgen stock traded at USD 439.51 on September 3, 2026, with a 52-week range of USD 269.77 to USD 447.03 and a market capitalization of USD 239.41 billion. The current quote is close to the top of that range and above the latest consensus target of USD 380.43 from MarketBeat.